Home
CMC Considerations for CAR T Cell Product Development
U.S. Food and Drug Administration
Apr 15, 2021
11,969 views
FDA’s Clinical Regulatory Perspective: Designing First-In-Human Trial for Cellular and Gene Therapy
Preclinical Considerations for Cell and Gene Therapy Products, an FDA Perspective
Designing First-In-Human Trials for Small Molecules and Biologics
Chemistry, Manufacturing Controls (CMC) in an Investigational New Drug (IND) (7/14) REdI 2017
Chemistry and Manufacturing Requirements for Early Clinical Development: What’s in there? Prove it.
FDA Clinical Investigator Training Course (CITC) 2022, Day 1 – Part 3
Chemistry, Manufacturing, and Controls (CMC) for an IND (7of14) REdI 2018
Regulatory Education for Industry (REdI) Annual Conference 2024: Day 1 – Session 3
Regulatory Education for Industry (REdI) Annual Conference 2024: Day 1 – Session 2
Post-approval Considerations for Changes to Manufacturing Process and Facilities - REdI 2020
Electronic Common Technical Document (eCTD)
Nonclinical Safety Assessment for Small Molecules and Biologic Drug Development (6of14) REdI 2018
Regulatory Education for Industry (REdI) Annual Conference 2024: Day 2 – Session 2
Introduction to the Drug Master File (DMF) Review Process
Panel Discussion
New Approaches for an Integrated Nonclinical-Clinical QT/Proarrhythmic Risk Assessment (1 of 2)
ICH M7(R1) – Chemistry and Manufacturing Control (CMC) Perspective on Hazard Assessment
FDA Omics Days 2024: Public afternoon sessions
Regulatory Education for Industry (REdI) Annual Conference 2024: Day 2 – Session 1
FDA Communication During Drug Development (4/14) REdI 2017